December 01, 2014
The Kennedy Trust for Rheumatology Research on Monday escaped a suit from a drugmaker that sought to have the court declare that its biosimilar arthritis medicine didn't infringe Kennedy's patents for Remicade when a judge found the two parties weren't actually adverse to one another yet.